ELAN
Elanco Animal Health Inc Health Care Pharmaceutical Preparations Russell 3000
$23.06Close
$11.5BMarket cap
$19.80 – $26.8452-week range
Nov 6, 2026Next report · before the open
Highlights
Strengths
- Earnings growing EPS +385% year on year, faster than the quarter before (+401 pts)
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 35 · weaker than 65% of stocks over 12 months
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 6, 2026, in 5 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 2.4%
price change
1mo
up 3.0%
price change
12-month return
up 2%
market up 11% ·
its own down 9%
F-score
4 / 9
Weak
Altman Z
1.25
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.8×
price / book
Earnings yield
down 1.5%
EBIT / enterprise value
Cheaper than
46%
of the market · around average
Revenue growth
up 6%
year on year
EPS growth
up 385%
latest quarter · +401 pts
Sales growth
up 10%
latest quarter · -5 pts
ROE
down 4%
return on equity
Free cash margin
up 6%
$284.0M FCF
D/E
0.61
long-term debt / equity
Net debt / EBITDA
7.6×
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- generating cash from operations
- profits backed by cash
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 6% ($4.3B → $4.0B)
Trade setup
ATR%
2.9%
$0.68 a day · 2×ATR $21.70
RS
35 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.64
50 sessions
Implied move
—
no option chain · report Nov 6, 2026
Trend template · 1 of 8
- Within 25% of the 52-week high: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Heavily indebted Net debt is 7.6 times EBITDA — roughly 8 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026-5% vs market2 sessions after results
Financials
- Gross 55%
- Net -5%
- Free cash 6%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.3B | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B |
| Gross margin | 49% | 55% | 57% | 56% | 55% | 55% |
| Net income | -$574.0M | -$483.0M | -$78.0M | -$1.2B | $338.0M | -$232.0M |
| Net margin | -18% | -10% | -2% | -28% | 8% | -5% |
| Earnings per share | -$1.30 | -$0.99 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
| Free cash flow | -$176.0M | $324.0M | $281.0M | $131.0M | $394.0M | $284.0M |
| Free cash margin | -5% | 7% | 6% | 3% | 9% | 6% |
| Cash | $495.0M | $638.0M | $345.0M | $352.0M | $468.0M | $545.0M |
| Long-term debt | $5.6B | $6.0B | $5.4B | $5.7B | $4.3B | $4.0B |
| Shareholders' equity | $8.5B | $7.5B | $7.3B | $6.2B | $6.1B | $6.5B |
| Shares outstanding | 471.92m | 473.12m | 474.24m | 492.85m | 494.45m | 496.98m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| May 27, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 24, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Dec 9, 2025 | Restructuring · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Nov 3, 2025 | Material agreement · New obligation ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 26, 2025 | Material agreement · New obligation ↗ |
| May 28, 2025 | Director or officer change · Regulation FD ↗ |
| May 21, 2025 | Shareholder vote ↗ |